Afamin in Gestational Diabetes Mellitus

Completed

• Conditions: Gestational Diabetes Mellitus in Pregnancy
• Interventions: Diagnostic Test: Afamin

• Registration Number: NCT04054843
• Lead Sponsor: Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital

Brief Summary

This study includes pregnancies in 11 to 14 th gestational weeks. Investigators will sample maternal plasma in the first trimester and analyze maternal plasma afamin values. All these women will then be screened by two step OGTT. Investigators will compare afamin levels in GDM and control groups.

Detailed Description

Background Gestational diabetes mellitus (GDM) is an endocrinopathy that occurs during pregnancy, and presents several clinical findings together with increased blood glucose levels. The frequency of GDM differs, while the incidence of the disease in Turkey is reported to be 7%. Most of the societies recommend screening all women with or without any risk factors in terms of GDM. The definitive diagnosis is made via oral glucose challenge test (OGTT). Early diagnosis and treatment are the key points to improve maternal and fetal outcomes. Different biomarkers are studied regarding GDM diagnosis starting from first trimester. However, there is not a worldwide accepted biomarker for defining the high risk group to the date. Afamin is known as an important indicator of oxidative stress. Moreover, oxidative stress itself is strongly associated with insulin resistance and obesity which are responsible from GDM pathogenesis.

Objective To investigate the association between first trimester maternal plasma afamin levels and GDM. Also, investigators aimed to understand the role of afamin for the prediction of GDM in this study.

Methods This is an observational prospective cohort study conducted in Department of Perinatology, Etlik Zubeyde Hanim Women's Health Care, Training and Research Hospital, University of Health Sciences, Ankara, Turkey. During 11 and 14 weeks of gestational, maternal blood will be obtained from eligible pregnant women, and samples will be stored at -80 oC. Informed written consent will be obtained from participants. Between 24th and 28th gestational weeks, all these women will be screened by two step OGTT. Then, afamin levels will be compared in GDM and control groups. Exclusion criteria are; multiple pregnancy, fetal anomalies, pregestational diabetes, underlying chronic diseases (hypertension, thyroid dysfunction, other endocrinopathies, autoimmune disorders), age \<18 or \> 35 years, fasting glucose level \> 105 mg/dL or random glucose level \> 200 mg/dL.

Study Timeline

• Study First Submitted: 2019-08-09
• Study First Submitted QC: 2019-08-10
• Study First Posted: 2019-08-13
• Study Start: 2019-09-01
• Primary Completion: 2020-03-01
• Study Completion: 2020-03-15
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-14
• Last Update Posted: 2020-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

• multiple pregnancy
• fetal anomalies
• pregestational diabetes
• underlying chronic diseases (hypertension, thyroid dysfunction, other endocrinopathies, autoimmune disorders)
• age <18 or > 35 years
• fasting glucose level > 105 mg/dL or random glucose level > 200 mg/dL

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Gestational diabetes mellitus	Afamin	First trimester pregnancies with gestational diabetes mellitus
Control	Afamin	First trimester healthy pregnancies

Primary Outcome Measures

Name	Time	Method
Maternal plasma afamin levels In first trimester GDM prediction	6 months	The predictive value of first trimester maternal plasma afamin levels for the diagnosis of gestational diabetes mellitus in comparison with two step OGTT

Trial Locations

Locations (1)

Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital; 🇹🇷 Ankara, Turkey